Dyne Therapeutics (NASDAQ:DYN) Now Covered by Evercore ISI

Evercore ISI began coverage on shares of Dyne Therapeutics (NASDAQ:DYN - Free Report) in a report released on Thursday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $46.00 price target on the stock.

Several other research analysts have also issued reports on DYN. Piper Sandler lowered their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Scotiabank initiated coverage on Dyne Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price target on the stock. Chardan Capital restated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Friday, May 9th. BMO Capital Markets assumed coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price objective for the company. Finally, HC Wainwright lowered their target price on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $45.54.

Dyne Therapeutics Trading Up 5.4%

DYN traded up $0.65 during trading on Thursday, reaching $12.61. 794,838 shares of the company's stock were exchanged, compared to its average volume of 1,626,947. Dyne Therapeutics has a one year low of $6.36 and a one year high of $47.45. The firm has a fifty day moving average price of $10.30 and a two-hundred day moving average price of $16.11. The stock has a market capitalization of $1.43 billion, a PE ratio of -3.58 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). Sell-side analysts expect that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC raised its holdings in Dyne Therapeutics by 162.2% during the 3rd quarter. Barclays PLC now owns 207,309 shares of the company's stock valued at $7,446,000 after acquiring an additional 128,246 shares during the period. KBC Group NV grew its position in shares of Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after purchasing an additional 978 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Dyne Therapeutics by 11.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company's stock valued at $508,000 after purchasing an additional 2,265 shares in the last quarter. abrdn plc bought a new stake in shares of Dyne Therapeutics during the 4th quarter valued at $608,000. Finally, Legato Capital Management LLC purchased a new stake in Dyne Therapeutics during the 4th quarter worth about $305,000. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.